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28 Chapter 2
Introduction
	 There	remains	a	pressing	need	for	additional	treatment	options	for	
mood	disorders,	particularly	those	refractory	or	difficult	to	treat	disorders	such	as	
bipolar	disorder.	Estimates	of	the	prevalence	of	bipolar	I	disorder	across	diverse	
cultures	and	ethnic	groups	are	consistent,	ranging	between	0.4%	and	1.6%	
in	adults	(Weissman	1996	and	Regeer	2004).	Recent	estimates	of	the	overall	
prevalence	of	bipolar	disorder	(types	I	and	II	as	well	as	NOS)	suggest	that	4-5%	
suffers	from	this	debilitating	mental	disorder	(Hirschfeld.2003;	Regeer	2004).	
Bipolar	disorders	carries	a	high	burden,	negatively	affecting	lives	in	many	areas,	
most	notably	the	performance	of	work-related,	leisure,	and	interpersonal	activities	
(Calabrese	2003).	The	greatest	need	exists	in	the	treatment	of	depressive	
episodes	associated	with	bipolar	disorders	as	symptoms	of	depression	are	much	
more	commonly	experienced	and	more	difficult	to	treat	than	manic	symptoms	
(Post	2002;	Judd	2002	and	Kupka	2005).
	 Reports	of	lamotrigine’s	beneficial	effects	on	mood	in	epilepsy	patients	
led	to	its	use	and	study	in	affective	disorders.	Studies	involving	bipolar	patients	
suggested	that	lamotrigine	possessed	a	broad	spectrum	of	therapeutic	activity	in	
bipolar	disorder,	with	later	descriptions	of	greater	efficacy	for	depressive	than	for	
manic	symptoms.	Given	the	significant	burden,	prevalence,	and	recurrent	nature	
of	bipolar	disorder	-	especially	bipolar	depression	–	lamotrigine	appears	to	begin	
to	address	an	area	of	serious	unmet	public	health	need	(Calabrese	2003).
Clinical Pharmacology of Lamotrigine
Pharmacodynamics
	 Lamotrigine	is	an	antiepileptic	drug	of	the	phenyltriazine	class	that	has	
demonstrated	efficacy	as	add-on	treatment	of	partial	seizures	(Mikati	1989;	
Matsuo	1993)	and	as	maintenance	treatment	of	bipolar	I	disorder	to	delay	
the	time	of	occurrence	of	mood	episodes	(Bowden	2003;	Calabrese	2003).	
Although	its	mechanism	of	therapeutic	action	in	humans	is	not	definitively	
understood,	lamotrigine	is	thought	to	possess	modulatory	and	protective	effects	
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on	neurotransmission	and	intracellular	signal	transduction	processes.
	 Structurally	distinct	from	other	antiepileptic	drugs,	lamotrigine	interacts	
preferentially	on	the	slow	inactivated	state	of	presynaptic	neuronal	sodium	and	
calcium	channels	to	prolong	inactivation	of	the	neuron	and	promote	stabilization	
of	the	neuronal	membrane	(Xie	1998).	This	effect	is	augmented	by	a	use-
dependent	action	in	which	further	inhibition	by	the	drug	develops	during	rapid,	
repetitive	stimulation	(i.e.,	epileptiform	bursts).	Consequently,	the	release	of	the	
excitatory	amino	acid	glutamate	is	antagonized	(Fitton	1995,	Li	and	Ketter	
2002).	Lamotrigine	has	also	been	observed	to	inhibit	cortical	and	amygdaloid	
kindling	(Gilman	1995,	Leach	1986	and	Xie	1995).
	 Lamotrigine	has	no	substantial	in	vitro	affinity	for	adenosine,	adrenergic,	
dopaminergic,	muscarinic	and	opioid	receptors	at	clinically	applicable	
concentrations	and	binds	only	weakly	to	inhibit	serotonin	5HT3	receptors	(Leach	
1991).	Lamotrigine	lacks	clinically	meaningful	activity	at	the	5HT1A	receptor,	
where	changes	in	5HT1A	receptor-mediated	cyclic	adenosine	monophosphate	
pathway	have	been	implicated	in	affective	disorders	(Shiah	1998	and	Vinod	
2002).
	 In	early	epilepsy	studies	with	lamotrigine	it	was	noted	that	many	patients	
reported	improvement	in	mood	and	psychological	well-being	independent	from	
reduction	in	seizure	frequency,	which	led	to	its	investigation	for	use	in	affective	
disorders	(Smith	1993a;	Smith	1993b).	Significantly,	lamotrigine	has	minimal	
negative	effects	on	cognitive,	memory,	or	psychomotor	function	and	is	not	
associated	with	sedative	effects	or	weight	gain	(Goa	1993,	Cohen	1985	and	
Ginsberg	2003).
Pharmacokinetics
	 Lamotrigine	is	extensively	absorbed	demonstrating	linear	kinetics,	
resulting	in	98%	bioavailability	(Garnett	1997).	Peak	plasma	concentrations	
are	attained	after	1-3	hours	with	mean	plasma	protein	binding	of	55-68%	
(Cohen	1987,	Ramsay,	1991	and	Rambeck	1993).	Lamotrigine	readily	crosses	
the	placental	barrier	causing	fetal	blood	concentrations	similar	to	maternal	
levels	and	passes	into	breast	milk	reaching	40-80%	of	the	maternal	lamotrigine	
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concentration	(Ohman,	2000	and	Pennell	2003).
	 The	rate-limiting	step	in	the	elimination	of	lamotrigine	is	
N-glucoronidation	by	the	liver	with	a	plasma	elimination	half-life	of	25	+	10	
hours	(Cohen	1987).	Autoinduction	of	its	own	metabolism	does	not	occur	and	
there	are	no	active	metabolites.	Pregnancy	increases	lamotrigine	clearance	by	
more	than	50%	early	during	pregnancy	and	reverts	quickly	after	delivery	(Tran	
2002).	Clearance	may	be	reduced	in	the	elderly	and	in	patients	with	moderate	
to	severe	hepatic	dysfunction.
Drug Interactions
	 Lamotrigine	administration	affects	hardly	the	serum	concentrations	
of	other	drugs.	However,	enzyme-inhibiting	drugs	such	as	divalproex	sodium	
increase	lamotrigine	concentrations	by	significantly	competing	for	metabolism	
through	glucoronidation	effectively	increasing	the	mean	half-life	of	lamotrigine	to	
about	70	hours	(Yuen	1992	and	Anderson	1996).	Enzyme-inducing	drugs,	such	
as	phenytoin,	carbamazepine,	and	phenobarbital,	reduce	the	lamotrigine’s	mean	
elimination	half-life	to	about	12	hours	and	decrease	lamotrigine	concentrations	
(Hachad	2002).	There	are	pharmacokinetic	interactions	between	lamotrigine	
and	anti-conceptive	medication.(Sidhu	2005).	The	clearance	of	levonogestrel	is	
increased	with	a	possible	decrease	of	the	anti-conceptive	reliability.	On	the	other	
hand	is	the	clearance	of	lamotrigine	enhanced	by	anti-conceptive	medication,	
with	a	lowering	of	lamotrigine	plasma	levels.
	 Lamotrigine	does	not	significantly	affect	the	pharmacokinetics	of	lithium	
(Chen	2000).
Lamotrigine and Mood Disorders
Acute treatment of bipolar depression
	 The	observations	of	Smith	and	colleagues	(Smith	1993a,	1993b)	
that	patients	treated	with	add-on	lamotrigine	for	partial	seizures	experienced	
improved	mood	apart	from	effects	on	epilepsy	stimulated	investigations	of	
lamotrigine’s	efficacy	to	treat	mood	disorders.	Early	case	reports	involving	
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bipolar	patients	suggested	that	lamotrigine	possessed	a	broad	spectrum	of	
therapeutic	activity	in	bipolar	disorder,	including	rapid	cycling	and	mixed	states	
(Weisler	1994,	Calabrese	1996	and	Walden	1996).	A	subsequent	open-label	
study	provided	preliminary	data	that	lamotrigine	was	effective	for	patients	with	
refractory	bipolar	disorder,	with	68%	of	depressed	patients	and	84%	of	manic	/	
hypomanic	/	mixed	patients	showing	moderate	to	marked	response	(Calabrese	
1999a).
	 An	open	naturalistic	study	of	twenty-two	depressed	bipolar	patients	
who	were	refractory	to	treatment	with	a	combination	of	divalproex	sodium	and	
another	mood	stabilizer	or	divalproex	sodium	and	an	antidepressant	for	6	weeks	
were	treated	with	add-on	lamotrigine.	Sixteen	out	of	22	(72%)	responded	by	the	
end	of	week	4,	suggesting	that	lamotrigine	may	be	useful	in	bipolar	depression	
(Kusumakar	1997).	In	a	double-blind	placebo-controlled	study	of	lamotrigine	
monotherapy	in	outpatients	with	non	rapid-cycling	bipolar	I	depression,	treatment	
with	lamotrigine	over	7	weeks	(50	or	200	mg/day)	did	not	result	in	a	significant	
difference	versus	placebo	on	the	primary	outcome	measure	(HAM-D),	but	did	so	
on	several	secondary	outcome	measures	including	the	MADRS,	particularly	in	the	
200	mg	group,	compared	with	placebo	(Calabrese	1999b).	Improvements	were	
observed	as	early	as	week	3.
	 After	this	first	positive	result	for	lamotrigine	in	a	RCT,	lamotrigine	was	
tested	against	placebo	in	four	other	RCT’s	(Calabrese	2007	and	Goldsmith	
2003).	None	of	these	RCT’s	discriminated	significantly	between	lamotrigine	and	
placebo	on	the	primary	outcome	criteria.	Part	of	this	negative	result	was	because	
of	a	high	placebo	response	in	all	four	studies.	Nevertheless,	a	meta-analysis	
of	all	five	studies	showed	a	significant	although	modest	benefit	for	lamotrigine.	
(Geddes	2009)
	 Thirty-one	patients	with	refractory	bipolar	and	unipolar	mood	disorders	
participated	in	a	double-blind,	randomized,	crossover	study	of	three	6-week	
monotherapy	evaluations	including	lamotrigine,	gabapentin,	and	placebo.	Using	
the	Clinical	Global	Impressions	Scale	for	Bipolar	Illness	(CGI-BP)	as	the	primary	
outcome	variable,	this	study	reported	a	52%	response	rate	(CGI-BP	as	much	or	
very	much	improved)	for	lamotrigine,	compared	to	26%	for	gabapentin	and	23%	
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for	placebo-treated	patients	(Frye	2000).
	 The	final	study	(n=410)	compared	lamotrigine	(dose	uptitrated	to	200	
mg/day)	with	olanzapine/fluoxetine	(dose	6/25,	6/50,	12/25	or	12/50	mg/
day)	(Brown.2006)	and	showed	a	small	but	significant	advantage	(improvement	
on	the	MADRS	after	7	weeks	of	14.91	vs	12.92	respectively	p=0.002)	for	the	
olanzapine/	fluoxetine	combination.
Acute treatment of mania / mixed states
	 The	1999	open-label	study	by	Calabrese	and	colleagues	observed	a	
robust	response	to	lamotrigine	(primarily	as	add-on	therapy)	in	84%	of	manic	
/	hypomanic	/	mixed	patients	(Calabrese	1999a).	In	the	first	double-blind,	
randomized,	controlled	study	of	lamotrigine	in	acute	mania	lamotrigine	titrated	
to	100	mg/day	over	three	weeks	was	as	effective	as	lithium	800	mg/day	(mean	
blood	level	0.77	mmol/L)	in	reducing	manic	symptoms	(Ichim	2000).	However,	
lamotrigine	has	not	shown	anti-manic	activity	in	placebo-controlled	studies	
(Bowden	2003).	Unpublished	studies	(data	on	file,	GlaxoSmithKline	2003)	in	
patients	with	acute	manic	or	mixed	exacerbations	of	bipolar	I	disorder	have	
found	no	significant	difference	from	baseline	in	the	11-item	Mania	Rating	Scale	
(MRS)	between	lamotrigine	and	placebo	(Goldsmith	2003).
Maintenance therapy
	 The	initial	lamotrigine	maintenance	study	was	a	double-blind,	placebo-
controlled	study	in	rapid	cycling	bipolar	disorder	(Calabrese	2000).	Open	label	
lamotrigine	added	to	the	treatment	regimens	of	324	patients	meeting	DSM-IV	
criteria	for	rapid	cycling	bipolar	disorder	resulted	in	182	stabilized	patients	
who	were	then	randomly	assigned	to	the	double-blind	maintenance	phase	after	
being	stratified	for	bipolar	I	or	II	disorder.	Other	psychotropic	agents	were	
tapered	and	patients	randomly	assigned	to	either	lamotrigine	monotherapy	or	
placebo	in	a	1:1	ratio	for	the	six-month	maintenance	phase.	Overall	49	placebo	
patients	(56%)	and	45	lamotrigine-treated	patients	(50%)	required	treatment	of	
an	emerging	mood	episode	with	additional	pharmacotherapy.	Although	there	
was	no	statistical	significance	between	these	two	treatment	groups	on	the	primary	
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outcome	measure	of	time	to	additional	pharmacotherapy	(median	of	12	weeks	
for	placebo	versus	18	weeks	for	lamotrigine),	lamotrigine	was	significantly	
more	effective	than	placebo	in	the	survival	in	study	analysis	(median	of	8	weeks	
for	placebo	versus	14	weeks	for	lamotrigine).	In	the	sub-analysis	according	
to	disease	type,	lamotrigine	was	significantly	more	effective	than	placebo	in	
delaying	time	to	additional	pharmacotherapy	for	bipolar	II	patients	than	bipolar	I	
patients.	Forty-six	percent	of	bipolar	II	patients	on	lamotrigine	monotherapy	were	
stable	without	relapse	after	6	months	compared	to	only	18%	of	placebo-treated	
bipolar	II	patients.	(Calabrese	2000).	These	results	were	confirmed	in	a	post	hoc	
analysis	of	the	same	patient	sample	with	the	Life	chart	method.	Measured	with	
the	life	chart	at	least	once	weekly	patients	taking	lamotrigine	were	1,8	times	
more	likely	to	achieve	euthymia	than	those	taking	placebo	(Goldberg	2008).	In	
an	unpublished	study	(data	on	file,	GlaxoSmithKline	2003),	these	findings	were	
not	replicated.	However,	significantly	fewer	lamotrigine	treated	rapid	cyclers	
required	intervention	for	a	depressive	episode.	Collectively,	these	results	suggest	
that	lamotrigine	may	be	a	useful	treatment	for	rapid	cycling	bipolar	patients,	
especially	for	type	II	and	for	the	prevention	of	depressive	relapses.
	 Two	18-month	maintenance	studies	(Bowden	2003	and	Calabrese	2003)	
comparing	lamotrigine,	lithium,	and	placebo	provided	further	support	for	the	use	
of	lamotrigine	as	a	mood	stabilizer	and	led	to	its	approval	by	the	US	FDA	in	June	
2003	as	a	maintenance	treatment	for	bipolar	I	disorder.	These	complementary	
studies	enrolled	patients	in	a	double-blind	phase	of	maintenance	therapy	after	a	
recent	depressed,	hypomanic,	or	manic	episode	remitted	(CGI-S	score	of	<	3	for	
4	consecutive	weeks)	during	open-label	stabilization	during	which	lamotrigine	
was	initiated	as	adjunctive	or	monotherapy	and	other	psychotropics	discontinued.	
In	both	studies,	50%	of	patients	achieved	stabilization	criteria	allowing	for	
progression	into	double-blinded	maintenance	therapy	with	lamotrigine	(50-400	
mg/day),	lithium	(0.8-1.1	mEq/L),	or	placebo.	The	primary	efficacy	endpoint	
used	was	time	to	intervention	for	any	mood	episode.
	 In	both	of	these	studies,	lamotrigine	and	lithium	demonstrated	effective	
prophylaxis	against	any	emerging	mood	episode	compared	with	placebo.	There	
were	statistically	fewer	relapsing	mood	episodes	and	longer	median	survival	in	
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lamotrigine	and	lithium	treated	patients	compared	with	placebo.	Median	survival	
before	intervention	for	any	mood	episode	for	lamotrigine-treated	patients	ranged	
from	118-256	days,	significantly	better	than	placebo	(85-93	days).	Lithium	also	
outperformed	placebo	with	a	median	survival	of	170-292	days.	However,	there	
were	important	differences	in	the	spectra	of	maintenance	efficacy.
	 In	both	studies,	lithium,	but	not	lamotrigine	was	superior	to	placebo	at	
delaying	the	time	to	intervention	for	a	manic	or	hypomanic	episode.	In	total	for	
both	studies	123	hypomanic/manic	events	emerged	during	maintenance,	with	
25%	of	placebo	treated	patients	experiencing	a	hypomanic,	manic,	or	mixed	
episode	(47	of	188);	21%	of	the	lamotrigine	group	relapsed	(58	of	273),	but	
only	11%	of	patients	in	the	lithium-treatment	arm	had	breakthrough	mania	or	
hypomania	(18	of	164).	Lithium	was	clearly	more	effective	than	placebo	and	
lamotrigine	in	preventing	manic	and	hypomanic	relapse	in	recently	symptomatic	
bipolar	I	patients.
	 In	contrast,	lamotrigine	appears	to	be	more	effective	than	lithium	in	the	
prevention	of	depressive	relapse	in	bipolar	I	patients.	In	both	studies,	lamotrigine	
but	not	lithium,	was	significantly	better	than	placebo	at	prolonging	time	to	
intervention	for	a	depressive	mood	episode.	There	were	209	depressive	relapses	
in	the	patients	observed	in	the	two	studies,	with	a	higher	rate	of	relapse	in	the	
placebo	(68	of	188,	or	36%)	and	lithium	treatment	groups	(56	of	164,	or	34%);	
lamotrigine	was	better	at	preventing	recurrence	of	depression	with	a	31%	rate	of	
depressive	relapse	and	a	longer	median	survival	before	treatment	of	depression	
was	necessary.	The	difference	was	particularly	evident	in	the	treatment	of	recently	
manic	or	hypomanic	patients	in	whom	only	14%	of	those	receiving	lamotrigine	
(8	of	58)	needed	intervention	for	emergent	depression	compared	with	23%	of	
patients	receiving	lithium	(10	of	44)	and	30%	receiving	placebo	(21	of	69).	In	
a	post	hoc	analysis	of	the	first	6	months	of	the	bipolar	I	patients	(index	episode	
depression)	there	was	no	evidence	for	a	greater	risk	for	mood	destabilization	
(emergent	(hypo)	manic	symptoms)	in	the	lamotrigine	group	versus	the	placebo	
group	(Goldberg	2009).
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Safety
Rash
	 Rashes	requiring	hospitalization	and	discontinuation	of	treatment	
have	been	reported	with	lamotrigine.	The	reported	rash	rate	is	10%	in	adult	
patients	with	epilepsy	treated	with	adjunctive	lamotrigine	and	7%	in	bipolar	I	
adults	treated	with	monotherapy;	the	placebo	rate	is	5%	in	both	populations	
(lamotrigine	package	insert).	Serious	rash	rates	are	considerably	lower	at	
0.8%	in	pediatric	epilepsy	patients,	0.3%	in	epileptic	adults	as	monotherapy	
and	0.13%	as	adjunctive	therapy.	A	retrospective	analysis	conducted	of	rates	
of	lamotrigine-related	rash	in	12	multicenter	studies	of	lamotrigine	for	mood	
disorders	(n=1955),	including	1	open	study,	7	randomized	controlled	acute	
trials,	and	4	randomized	controlled	maintenance	trials	from	1996	to	2001	
reported	serious	rash	in	0%	with	lamotrigine,	0.1%	(n	=	1)	with	placebo,	and	
0%	with	comparators	(Calabrese	2002).	Across	all	bipolar	disorder	studies	with	
2,272	patients	on	lamotrigine,	serious	rash	was	observed	in	three	patients	for	
an	overall	rate	of	0.1%	(lamotrigine	package	insert).	One	of	these	three	patients	
experienced	a	mild	Stevens-Johnson	syndrome	on	adjunctive	lamotrigine	and	did	
not	require	hospitalization.
	 In	a	randomized	trial	Usual	Care	Precautions	were	compared	with	
Dermatologic	Precautions	(UCP	plus	additional	specific	precautions	intended	to	
decrease	the	risk	of	rash)	for	12	weeks	(Ketter	2006).	Lamotrigine	was	added	
(target	dose	200mg/day)	to	ongoing	medication	with	a	slow	up	titration.
Usual	Care	precautions	were:
1.	not	exceeding	the	initial	dose	or	dose-escalation	schedule
2.	if	a	rash	developed	during	the	study	the	patient	contacted	the	investigator	
immediately
3.	lamotrigine	was	stopped	in	case	of	rash.
Patients	in	the	Dermatologic	Precautions	group	were,	besides	UCP,	advised	not	
to:
4.	take	new	medications	or	foods,	use	new	cosmetics,	deodorants,	detergents	or	
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fabric	softeners
5.	stimulate	the	immune	system	through	excessive	sun	exposure
6.	participate	in	activities	that	might	lead	to	exposure	to	poison	oak	or	poison	ivy
7.	receive	any	immunizations
	 1175	patients	were	included.	In	both	groups	there	were	no	reports	of	
serious	rash.	The	rate	of	non-serious	rash	was	low	for	UCP	as	well	as	for	DP	
(8.8%	and	8.6%	respectively,	OR	0.99).	which	is	comparable	with	rates	of	rash	
in	previous	studies.	Clinical	response	was	50%	with	29%	remission	over	both	
groups	(according	to	the	Clinical	Global	Impressions	Bipolar	version).
	 A	German	registry	that	documents	the	incidences	of	serious	rash	has	
been	in	place	since	1990	and	ascertains	hospitalized	cases	of	Stevens-Johnson	
syndrome	(SJS)	and	toxic	epidermal	necrolysis	(TEN)	related	to	antiepileptic	
drug	use	(Rzany	1996).	Reported	cases	are	confirmed	by	a	registry	physician	
and	reviewed	by	a	dermatological	expert	committee	ensuring	high	diagnostic	
accuracy.	The	incidence	of	serious	rash	rising	to	the	level	of	SJS/TEN	diagnosis	
in	the	German	registry	was	0.02%	from	1993-2001	(Messenheimer	2002).
	 Risk	of	rash	is	noted	to	be	higher	in	pediatric	patients	and	may	
be	increased	by	co-administration	of	divalproex	sodium	or	exceeding	the	
recommended	initial	dose	or	dose	escalation	schedule	for	lamotrigine.	Women	
may	be	at	increased	risk	for	rash	compared	with	men,	with	a	relative	risk	of	1.8	
(Wong	1999).
Other side effects and tolerability
	 Lamotrigine	is	known	to	be	generally	well	tolerated	in	the	treatment	
of	epilepsy	(Choi	2003).	A	great	deal	of	data	generated	by	the	18-month	
lamotrigine	maintenance	trials	(Bowden	2003	and	Calabrese	2003)	confirms	
clinical	experience	and	epilepsy	management	reports	of	lamotrigine’s	favorable	
side	effect	profile	in	the	treatment	of	bipolar	patients.	In	280	patients	on	
maintenance	lamotrigine	during	double-blinded	treatment	in	both	trials	combined,	
only	23	(8.2%)	discontinued	study	participation	prematurely	due	to	an	adverse	
event;	7.9%	of	placebo	treated	patients	experienced	adverse	events	that	led	to	
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end	of	study	(15	of	191).	Over	the	18	months	randomized	phase,	lamotrigine	
treated	patients	exhibited	a	4.9	pound	mean	decrease	in	body	weight,	compared	
to	a	2.6	pound	mean	weight	gain	in	the	placebo	group.	In	a	combined	analysis	
of	both	studies,	the	incidence	of	mania/	hypomania/	mixed	episodes	reported	
as	adverse	events	was	5%	for	patients	treated	with	lamotrigine,	4%	for	patients	
treated	with	lithium,	and	7%	for	patients	treated	with	placebo.	In	general,	
lamotrigine	exhibits	placebo	level	rates	of	treatment-emergent	adverse	events	and	
is	better	tolerated	than	lithium	(Calabrese	2003).	Table	1	lists	treatment-emergent	
adverse	events	for	the	combined	maintenance	studies	during	randomized	phase.
Table 1. Adverse	events	observed	during	randomized	phase	of	lamotrigine	maintenance	
studies	(in	percent)*
Event Lamotrigine	(n	=	227) Placebo	(n	=	190)
Nausea 14 11
Insomnia 10 6
Somnolence 9 7
Back	pain 8 6
Fatigue 8 5
Rhinitis 7 4
Benign	rash 7 5
Abdominal	pain 6 3
Dry	mouth 6 4
Constipation 5 2
Vomiting 5 2
Cough	exacerbation 5 3
Pharyngitis 5 4
*		Adverse	events	listed	had	incidence	>	5%	and	were	numerically	greater	than	placebo.	
[Bowden	2003;	Calabrese	2003;	Data	on	file,	GlaxoSmithKline]
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Clinical applications for lamotrigine
Bipolar depression
	 For	the	management	of	acute	bipolar	depression,	the	APA	Practice	
Guidelines	of	2002	recommended	lamotrigine	as	a	first-line	option	with	
moderate	clinical	confidence	(Hirschfeld	2002).	Since	then	other	options	have	
become	available,	especially	quetiapine	and	the	combination	of	olanzapine	
plus	fluoxetine.	With	the	data	that	became	available	after	the	2002	guideline,	
lamotrigine	has	a	place	in	the	treatment	of	acute	bipolar	depression,	especially	
in	patients	experiencing	a	depressive	episode	despite	adequate	treatment	with	
lithium.	In	these	patients	lamotrigine	can	be	recommended	as	add-on	therapy	
with	substantial	clinical	confidence.
	 Dosing	should	follow	published	titration	schedules	to	minimize	the	risk	
of	rash,	with	a	minimum	dose	of	50	mg/day	and	a	target	dose	of	200	mg/
day	for	most	patients	(table	2).	There	is	no	pharmacokinetic	interaction	with	
lithium,	However,	in	bipolar	patients	experiencing	a	breakthrough	depression	on	
carbamazepine	or	valproate,	lamotrigine	should	be	added	while	keeping	in	mind	
pharmacokinetic	interactions	that	may	affect	dosing:	double	dose	of	lamotrigine	
in	combination	with	carbamazepine,	half	the	dose	in	combination	with	valproate.
Table 2. Recommended	Lamotrigine	dosing	schedule
Concomitant	
medication?
Week	
1	&	2
Week		
3	&	4
Week	5 Week	6 Week	7
Not	on	divalproex	or	
carbamazepine
25	mg	qd 50	mg	qd 100	mg	
qd
200	mg	
qd
200	mg	
qd
On	divalproex 25	mg	
qod
25	mg	qd 50	mg	qd 100	mg	
qd
100	mg	
qd
On	carbamazepine	
or	phenytoin
50	mg	qd 100	mg	
qd
200	mg	
qd
300	mg	
qd
300	mg	
qd
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Mania / mixed states
	 Lamotrigine	monotherapy	is	not	recommended	for	the	acute	management	
of	mania	or	mixed	states	associated	with	bipolar	I	disorder.	Despite	limited	
case	reports	and	early	data	suggesting	that	lamotrigine	may	possess	anti-manic	
properties,	further	study	has	led	to	the	conclusion	that	lamotrigine	has	only	mild	
to	moderate	efficacy	in	mania	and	should	not	be	reliably	used	as	monotherapy	
in	these	urgent	above	baseline	mood	disturbances.	The	addition	of	lamotrigine	
to	other	first-line	antimanic	agents,	such	as	lithium,	divalproex,	olanzapine,	or	
quetiapine	may	hasten	or	complete	recovery	from	acute	manic	or	mixed	states.	
Lamotrigine	should	definitely	be	considered	as	an	initial	adjunctive	treatment	for	
these	bipolar	I	patients	to	address	the	need	to	prevent	future	mood	episodes	after	
recovery	from	the	current	manic	or	mixed	episode.	Again,	dosing	guidelines	
should	be	followed	as	indicated	previously	and	in	the	package	insert	to	avoid	
increased	risk	of	rash.
	 In	bipolar	II	patients	experiencing	acute	hypomania,	lamotrigine	can	be	
used	as	a	monotherapy	or	in	conjunction	with	another	mood	stabilizer	such	as	
lithium.	One	effective	strategy	is	the	prescription	of	lamotrigine	plus	a	short-term	
atypical	antipsychotic
Maintenance therapy
	 Lamotrigine	is	indicated	by	the	US	FDA	and	the	EMEA	for	the	
maintenance	treatment	of	bipolar	I	disorder	to	delay	the	time	to	occurrence	of	
mood	episodes.	It	should	therefore	be	considered	in	the	treatment	of	all	bipolar	
patients	due	to	the	inherent	natural	tendency	for	the	illness	to	be	chronic	and	
recurrent.
	 Maintenance	monotherapy	with	lamotrigine	can	be	considered	in	those	
individuals	with	non-bipolar	I	illness,	milder	forms	of	bipolar	II	disorder	with	
predominant	depressive	course,	and	in	other	bipolar	spectrum	disorders	such	
as	cyclothymic	or	hyperthymic	personalities.	In	theory,	lamotrigine	monotherapy	
could	also	be	considered	as	a	maintenance	therapy	after	successful	ECT	for	either	
unipolar	or	bipolar	depression.	In	most	patients,	lamotrigine	should	be	part	of	
a	combined	pharmacological	strategy	to	prevent	relapse.	Although	lamotrigine	
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has	been	demonstrated	an	effective	maintenance	treatment	for	bipolar	I	
disorder,	its	ability	to	prevent	manic	episodes	was	considerably	less	robust	than	
its	antidepressant	ability.	A	comprehensive	bipolar	maintenance	medication	
treatment	plan	must	address	prevention	of	depressive	and	manic	phases,	
and	lamotrigine	is	only	moderately	effective	in	the	delay	of	manic	episodes	
necessitating	use	of	other	mood	stabilizers	with	a	complementary	efficacy	profile,	
such	as	lithium,	divalproex.or	atypical	antipsychotics.
Use in women
	 There	have	been	reports	of	lamotrigine	serum	concentrations	
decreasing	in	women	after	starting	oral	contraceptives	and	increasing	after	oral	
contraceptives	were	discontinued	(Sidhu	2005).	Dosage	adjustments	may	have	
to	be	made	in	women	taking	lamotrigine	during	times	of	oral	contraceptive	
initiation	or	termination,	although	no	known	link	exists	between	blood	levels	and	
therapeutic	effects	for	affective	disorders.
	 Lamotrigine	carries	a	Category	C	FDA	warning	for	use	during	
pregnancy.	Pregnant	women	maintained	on	lamotrigine	during	pregnancy	should	
have	blood	levels	of	lamotrigine	checked	monthly	as	its	clearance	increases	
significantly	as	pregnancy	progresses.	A	preconception	determination	of	
lamotrigine	blood	level	in	a	stable	bipolar	woman	may	provide	a	target	dose	
range	to	maintain	during	pregnancy.	Clearance	of	lamotrigine	drops	quickly	
after	delivery,	requiring	dosage	reduction	in	most	postpartum	patients.	Breast-
feeding	is	not	recommended	to	nursing	mothers	on	lamotrigine	since	significant	
levels	of	lamotrigine	are	present	in	breast	milk	and	long	term	effects	of	exposure	
to	neonates	is	unknown.	Although	there	are	some	reports	of	an	increased	risk	for	
isolated	cleft	palate	or	lip	deformity	after	exposure	to	lamotrigine	monotherapy	
during	the	first	trimester	of	pregnancy	(Holmes	2008)	the	overall	risk	for	major	
birth	defects	appear	to	be	similar	to	that	of	the	general	population	(Cunnington	
2005).
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Summary
	 The	discovery	of	lamotrigine’s	positive	effects	on	mood	in	epilepsy	
patients	led	to	its	investigations	in	and	eventual	approval	for	treating	bipolar	I	
disorder.	Although	the	exact	mood	stabilizing	mechanism	of	action	for	this	novel	
anticonvulsant	is	unknown,	it	is	thought	to	work	by	inhibiting	voltage-sensitive	
sodium	currents,	in	this	manner	stabilizing	neuronal	membranes	and	as	a	result	
modulating	the	presynaptic	transmitter	release	of	excitatory	amino	acids	such	as	
glutamate.	It	is	approved	for	maintenance	treatment	of	bipolar	disorder	to	prevent	
depressive	episodes.	In	addition,	it	deserves	a	place	in	the	treatment	of	acute	
bipolar	depression,	with	the	strongest	evidence	as	add-on	treatment	to	lithium	
(this	thesis).	Lamotrigine	is	well	tolerated,	the	major	risk	is	a	severe	rash,	and	it	
requires	careful	dose	monitoring.
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